Paul Hastings Wins Hatch-Waxman Litigation Firm of the Year at LMG Life Sciences Awards
September 13, 2018
Takeaways from Federal Circuit’s Decision in UCB v. Accord on Obviousness of Chemical Compounds
June 04, 2018
Federal Circuit Provides Additional Guidance for Induced Infringement in Hatch-Waxman Cases
November 13, 2017
Recognized at the 2016 LMG Life Sciences Awards
Paul Hastings was recognized with multiple LMG Life Sciences Awards. Bruce Wexler was named “General Patent Litigator of the Year – New York” and Naveen Modi was recognized as Post Grant Proceedings Attorney of the Year. The Life Sciences Patent Litigation practice also won awards for two Hatch-Waxman Impact Cases of the Year, including Helsinn Healthcare SA v. Teva Pharmaceuticals USA, a win resolving a long-running patent dispute over Aloxi®, a drug used to treat chemotherapy-induced nausea and vomiting.
The Paul Hastings team representing Helsinn was led by Joseph O’Malley. The firm was also honored for its work on behalf of Eli Lily in Sanofi-Aventis US v. Eli Lilly & Co., where Bruce Wexler led the team representing Eli Lily in litigation regarding the marketing of Basaglar®, its insulin glargine drug product. The case was settled in late 2015, with the press reporting Eli Lilly’s ability to launch the drug.
September 16, 2016
Shortlisted for four LMG Life Sciences Awards for 2016
The Firm was shortlisted in four categories for the LMG Life Sciences Awards. Joseph O’Malley was nominated in the Hatch-Waxman Litigator of the Year – Branded category, Bruce Wexler was nominated in the General Patent Litigator of the Year - New Yorkcategory, Naveen Modi was nominated in the Post Grant Proceedings Attorney of the Year category, and the Firm was nominated in the “Hatch-Waxman Litigation Firm of the Year – Branded” category.
July 27, 2016